1. Home
  2. PFO vs GNLX Comparison

PFO vs GNLX Comparison

Compare PFO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

PFO

Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

HOLD

Current Price

$9.03

Market Cap

118.6M

Sector

Finance

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.88

Market Cap

133.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFO
GNLX
Founded
1991
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.6M
133.0M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PFO
GNLX
Price
$9.03
$2.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
21.1K
169.4K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
6.51%
N/A
EPS Growth
N/A
9.47
EPS
N/A
N/A
Revenue
N/A
$8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.85
$2.29
52 Week High
$9.90
$8.54

Technical Indicators

Market Signals
Indicator
PFO
GNLX
Relative Strength Index (RSI) 31.22 46.82
Support Level $8.95 $2.73
Resistance Level $9.27 $2.94
Average True Range (ATR) 0.06 0.12
MACD -0.02 -0.00
Stochastic Oscillator 4.00 33.33

Price Performance

Historical Comparison
PFO
GNLX

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: